About Us

At Cytovation, we are on a mission to make immunotherapy effective across a wide range of cancer types.

About
us

At Cytovation, we are on a mission to make immunotherapy effective across a wide range of cancer types.

Who We Are

Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering highly stable synthetic peptides with unique, antitumoral properties.

CyPep-1, the company’s lead candidate is being developed as a novel, first-in-class immunotherapy, that drives a tumor-specific immune response with a dual mode of action.

Management

CEO

Lars Prestegarden

COO/CFO

Federico Grego

Chief Development Officer

Iman Barilero

Head of Clinical Development

Cesar Pico

Vice President of Operations

Helén Johansen Blanco

Clinical Project Manager

Jeanette Kamman

Lead CRA

Sandra Jansen

Deputy CFO

Vetle Veiteberg

Advisors

Rolf Bjerkvig

Ole-Erik Iversen

Bo Jesper Hansen

Raj Airey

Board

Chairman

Stein-Christian Mohn

Board Member

Liv H. Dyrnes

Board Member

Olav Hellebø

Board Member

Øyvind Kongstun Arnesen

Board Member

Hilde Hukkelberg